• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    6/16/25 4:06:22 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRX alert in real time by email
    flks-20250611
    0001615219FALSE00016152192024-09-272024-09-27

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 11, 2025
    SALARIUS PHARMACEUTICALS, INC.
    (Exact name of registrant as specified in its charter)
    Delaware 001-36812 46-5087339
    (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
         
    2450 Holcombe Blvd.
    Suite X
    Houston, TX
     77021
    (Address of principal executive offices) (Zip Code)
    (713) 913-5608
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.0001
    SLRX
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐



    Item 8.01. Other Events

    On June 11, 2025, Salarius Pharmaceuticals, Inc. (“Salarius”) received written notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Hearings Panel”) has granted Salarius an extension to regain compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). The extension by the Hearing Panel is contingent on Salarius achieving scheduled milestones and notifying Nasdaq of such achievements. Such milestones consist of regaining compliance with the Equity Standard by early July 2025 and regaining compliance with the Minimum Bid Price Requirement by early August 2025. If Salarius is not successful at satisfying these milestones within the time periods prescribed by the Hearings Panel, the Hearings Panel may revoke the extension.

    As previously disclosed, on April 23, 2025, Salarius received written notice (the “Delisting Notice”) from Nasdaq notifying Salarius that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius’ common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would have been afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), Salarius was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because Salarius had effected a reverse stock split during the prior one-year period. In addition, as previously disclosed, on March 26, 2025, Salarius received a letter from Nasdaq notifying Salarius that, based on its Form 10-K for the year ended December 31, 2024, Salarius no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market (the “Equity Standard”). The letter indicated that Salarius had until May 12, 2025, to either regain compliance with the Equity Standard or submit a plan to Nasdaq to regain compliance with the Equity Standard (a “Compliance Plan”). However, pursuant to Nasdaq Listing Rule 5810(d)(2), Salarius’ failure to comply with the Minimum Bid Price Requirement served as a separate and additional reason for delisting and, as such, the Delisting Notice indicated that Nasdaq would not entertain a Compliance Plan, and that it should address Salarius’ noncompliance with the Equity Standard before the Hearings Panel if Salarius appealed Nasdaq’s determination.

    Salarius timely exercised its right to request a hearing to appeal the delisting determination, which stayed the suspension of Salarius’ securities and the filing of the Form 25-NSE pending the Hearings Panel’s decision. The hearing before the Hearings Panel took place on June 3, 2025.













    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    SALARIUS PHARMACEUTICALS, INC.
    Date: June 16, 2025
    By:
    /s/ Mark J. Rosenblum
    Mark J. Rosenblum
    Executive Vice President & Chief Financial Officer
    Get the next $SLRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SLRX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    8/25/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

      CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therapeutics, announced that a series of antiviral drug candidates previously designed by its IMP3ACT™ platform to be broadly effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles and Nipah viruses. As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) signed a definitive merger agreement pursuant to which Decoy will merge with a wholly owned subsidiary of Salarius, subject to satisfaction of th

      3/26/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

      Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates expected later this year from the MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today repor

      3/24/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Arthur David J.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      4/12/24 4:50:27 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rosenblum Mark J

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:37:10 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcvicar William K.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:29:33 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Salarius Pharmaceuticals Inc.

      S-1/A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/16/25 5:01:52 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/16/25 4:06:22 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/11/25 8:38:51 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      3/11/22 6:32:47 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      8/25/21 6:10:11 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      11/14/24 4:38:31 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

      SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/14/24 3:54:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/13/23 4:30:18 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

      HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

      2/3/22 7:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Financials

    Live finance-specific insights

    See more
    • Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

      HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

      12/8/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

      60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

      12/1/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

      8/8/22 8:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care